Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder

Li, Yulin; Liu, Yanyan; Zhao, Wenjin; An, Xueting; Zhang, Fenghe; Zhang, Tian-Xiang; Liu, Ye; Du, Chen; Zeng, Pei; Yuan, Meng; Zhang, Ningnannan; Zhang, Chao

doi:10.1016/j.jneuroim.2023.578218

Journal of Neuroimmunology

2023

DOI: 10.1016/j.jneuroim.2023.578218

|View full text |Cite

Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder

Yulin Li,

Yanyan Liu,

Wenjin Zhao

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Lorefice,

Cortese

2024

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Lorefice,

Cortese

2024

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis

Shaygannejad,

Rafiei,

Vaheb

et al. 2024

Medicina

View full text Add to dashboard Cite

There is debate on the role of glial fibrillary acidic protein (GFAP) as a reliable biomarker in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), and its potential to reflect disease progression. This review aimed to investigate the role of GFAP in MS and NMOSD. A systematic search of electronic databases, including PubMed, Embase, Scopus, and Web of Sciences, was conducted up to 20 December 2023 to identify studies that measured GFAP levels in people with MS (PwMS) and people with NMOSD (PwNMOSD). R software version 4.3.3. with the random-effect model was used to pool the effect size with its 95% confidence interval (CI). Of 4109 studies, 49 studies met our inclusion criteria encompassing 3491 PwMS, 849 PwNMOSD, and 1046 healthy controls (HCs). The analyses indicated that the cerebrospinal fluid level of GFAP (cGFAP) and serum level of GFAP (sGFAP) were significantly higher in PwMS than HCs (SMD = 0.7, 95% CI: 0.54 to 0.86, p < 0.001, I2 = 29%, and SMD = 0.54, 95% CI: 0.1 to 0.99, p = 0.02, I2 = 90%, respectively). The sGFAP was significantly higher in PwNMOSD than in HCs (SMD = 0.9, 95% CI: 0.73 to 1.07, p < 0.001, I2 = 10%). Among PwMS, the Expanded Disability Status Scale (EDSS) exhibited significant correlations with cGFAP (r = 0.43, 95% CI: 0.26 to 0.59, p < 0.001, I2 = 91%) and sGFAP (r = 0.36, 95% CI: 0.23 to 0.49, p < 0.001, I2 = 78%). Regarding that GFAP is increased in MS and NMOSD and has correlations with disease features, it can be a potential biomarker in MS and NMOSD and indicate the disease progression and disability in these disorders.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder

Cited by 2 publications

References 23 publications

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About